2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f [g] h i j k l m n o p q r s t u v w x y z

Abstract Number: 1161

Gadolinium-Enhanced Magnetic Resonance Imaging in Shoulders Contributes Accurate Diagnosis and Predicting Recurrence to Patients with Polymyalgia Rheumatica
Abstract Number: 1864

Gaps in Care for Patients with SLE: Data from the ACR’s RISE Registry
Abstract Number: 264

Gaps in Patient Safety Performance in Patients with Immunosuppressive Therapy: Results of Screening for Infections and Vaccination Status in a Large Real-life Cohort
Abstract Number: 2237

Gathering Patients’ and Physicians’ Perceptions to Improve Outcomes in Systemic Autoimmune Myopathies
Abstract Number: 1873

Geisinger HiROC Performance 2017-2018: Continuing to Narrow the Post-Fracture Treatment Gap
Abstract Number: 577

Gender Contrasts in Patient Reported Outcomes Don’t Alter the Disease Activity Score in Axial Spondyloarthritis Patients
Abstract Number: 629

Gender Differences in Comorbidities and Treatment Utilization Among Ankylosing Spondylitis Patients Initiating a Biologic in a Real-World Setting
Abstract Number: 2446

Gender Differences in Psoriatic Arthritis – Impact on Tumor Necrosis Factor Inhibitors Persistence and Response
Abstract Number: 2484

Gender Influence on Treatment Effectiveness in Psoriatic Arthritis
Abstract Number: 1866

Gene Expression Meta-Analysis Reveals Commonalities in Gene Activation and Enrichment of Immune Pathways and Cell Types in Dermatomyositis Target Tissues
Abstract Number: 2023

Gene-Expression Analysis of Male and Female SLE Patients Reveals Candidate Pathogenic Pathways
Abstract Number: 1952

Genes Associated with Nucleotide Oligomerization Domain-Like Receptor Signaling Pathway Are Upregulated in Discoid Lupus Erythematosus
Abstract Number: 1004

Genetic Ablation of γδTCR Inhibits IL-23-induced Neutrophilia and Attenuates Epidermal Hyperplasia, Synovitis, Onycholysis and Enthesitis Associated with Psoriatic Arthritis
Abstract Number: 1932

Genetic Evidence for Recent Positive Selection of the HLA-B*51:01 Allele in the Turkish Population, a Population with a High Prevalence of HLA-B*51-Associated Behçet’s Disease
Abstract Number: 776

Genetic Signatures Support Inflammation Driven Fibrosis in Localized Scleroderma
Abstract Number: 2024

Genetics of Longitudinal Kidney Function in Children and Adults with Systemic Lupus Erythematosus
Abstract Number: 1942

Genome-wide Association Study in a Japanese Population Revealed Novel Candidate Genes for Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Abstract Number: 1050

Genome-Wide DNA Methylation Signatures in Classical Monocytes from African Ancestry Patients with Systemic Sclerosis
Abstract Number: 1718

Geographic Disparities in Mortality Rates of Vasculitis in the United States: 1999 to 2017
Abstract Number: 2917

Geographic Disparities in Systemic Sclerosis Mortality in the United States: 1999 to 2017
Abstract Number: 2658

Giant Cell Arteritis Diagnostic Workup Among Medicare Beneficiaries
Abstract Number: 2670

Giant Cell Arteritis with Intracranial Vasculitis: A Case Series
Abstract Number: 2659

Giant-Cell Arteritis Associated with Myeloproliferative Neoplasms: A Retrospective Case–Control Study
Abstract Number: 1995

Gingival-Derived Mesenchymal Stem Cells Alleviate Cartilage Damage in Collagen-Induced Arthritis via Suppressing Activities of Inflamed Synovial Fibroblast
Abstract Number: L16

GLCCI1 Polymorphism Is Associated with Prednisone Response in Giant Cell Arteritis: A Multicenter Prospective Study
Abstract Number: 416

Global Management of Patients with Knee Osteoarthritis Begins with Quality of Life Assessment: A Systematic Review
Abstract Number: 1379

Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study
Abstract Number: 1383

Glucocorticoid Tapering in Monthly 1-mg Decrements Does Not Result in Clinically Manifest Adrenal Insufficiency in Patients with Rheumatoid Arthritis: Learnings from a Phase 3/4 Study
Abstract Number: 1665

Glucocorticoids in Incident ANCA-Associated Vasculitis (AAV) Patients – A Study of Routine Clinical Practice in the EU Demonstrates Prolonged Use and Temporal Relationship to Adverse Events and Infections
Abstract Number: 1688

Glucocorticoids Plus Rituximab versus Glucocorticoids Plus Placebo in Non-infectious Active Mixed Cryoglobulinemia Vasculitis: Results of a Placebo-Controlled Randomized Trial
Abstract Number: 2562

Glucocorticosteroid Usage and Major Organ Damage in Patients with Systemic Lupus Erythematosus – Meta-analyses of Observational Studies Published Between 1979 and 2018
Abstract Number: 1766

GM-CSF Is a Pro-Inflammatory Cytokine in Experimental Vasculitis of Medium and Large Arteries
Abstract Number: 2689

GM-CSF Pathway Signature Identified in Temporal Artery Biopsies of Patients with Giant Cell Arteritis
Abstract Number: 2876

Go-Dact: A Phase 3b Randomized Double-Blind Placebo-Controled Proof-Of-Concept Trial, of Golimumab Plus Methotrexate (MTX) versus MTX Monotherapy, in Improving Dactylitis, in MTX Naïve Psoriatic Arthritis Patients
Abstract Number: 1446

Golimumab as First, Second or at Least Third Biologic Agent in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Post Hoc Analysis of a Non-Interventional Study in Germany
Abstract Number: 1477

Golimumab Improves Direct Costs of Healthcare Utilization and Indirect Costs Within Patients with RA, PsA, and as – Analysis of a Non-Interventional Study in Germany
Abstract Number: 1087

Golimumab Improves Work Productivity and Activity and Quality of Life in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Final Results from a Non-Interventional Study in Germany (GO-ART)
Abstract Number: 1499

Golimumab Persistence in Biologic Naive and Non-Naive Patients with Axial Spondyloarthritis: Results of the GO PRACTICE Study
Abstract Number: 228

Good Pain, Bad Pain: Illness Perception and Physicians Attitude Towards Rheumatoid Arthritis and Fibromyalgia Patients
Abstract Number: 1183

Gout and Serum Urate Levels Are Associated with Lumbar Spine Monosodium Urate Deposition and Chronic Low Back Pain: A Dual-Energy CT Study
Abstract Number: 356

Gout Flares Become Infrequent During a Treat-to-target Strategy over One Year: Data from the NOR-Gout Study
Abstract Number: 337

Gout in the US: Significant Association with Cardiovascular and Renal Disease Hospitalizations – A Nationwide Study
Abstract Number: 331

Gout Management in the Medical Community: A Claims-Based Analysis
Abstract Number: 1117

Government Subsidization of Biologic Therapy for Inflammatory Arthritis in a Co-Funded Healthcare Model: A Singapore Experience
Abstract Number: 872

Granulomatosis with Polyangiitis Sustained Remission Off-Therapy: Data from the French Vasculitis Study Group Registry
Abstract Number: 1668

Granulomatosis with Polyangiitis: Data from the French Vasculitis Study Group Registry
Abstract Number: 33

GS-4875, a First-in-Class TPL2 Inhibitor Suppresses MEK-ERK Inflammatory Signaling and Proinflammatory Cytokine Production in Primary Human Monocytes
Abstract Number: 2569

Guidelines on Prescribing and Monitoring Antimalarials in Rheumatic Diseases: A Systematic Review
Abstract Number: 1494

Guselkumab Was More Effective Than Secukinumab in Patients with Plaque Psoriasis and the Subset of Patients with Self-Reported Psoriatic Arthritis in a Randomized, Double-blind, Head-to-head Comparison Study over 1 Year
Abstract Number: L13

Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study
Abstract Number: 807

Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis Who Were Biologic-Naïve or Prior TNFα Inhibitor-Treated: Week 24 Results of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Abstract Number: 2317

Gut Dysbiosis Is Associated with Measures of Early Vascular Dysfunction in Patients with Rheumatoid Arthritis

Jump to: View All • a b c d e f [g] h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].